-
Imprimis Launches 99-Cent Generic Drug To Compete With Allergan's Restasis
Thursday, October 19, 2017 - 7:50am | 569Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) announced Thursday the release of a 99-cent alternative to Allergan PLC Ordinary Shares (NYSE: AGN)'s Restasis to address the 30 million Americans suffering from Dry Eye Disease. According to Imprimis, Restasis lacks generic competition despite a...
-
Imprimis Challenges Mallinckrodt's Acthar
Tuesday, March 21, 2017 - 4:33pm | 462Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) wants to stop egregious drug pricing issues, and Mallinckrodt PLC (NYSE: MNK) is its next target. Imprimis announced it will pursue a lower priced alternative to Mallinckrodt's HP Acthar Gel, which grossed sales of $1.3 billion in the prior year....
-
Imprimis CEO Talks Phenomenal Quarter: 'Shocking' Statistics, Simplification And A Trifecta For Success
Thursday, December 1, 2016 - 1:03pm | 510Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) is a San Diego-based small-cap pharmaceutical company that specializes in the ophthalmology space. The company is coming off an impressive 81 percent year-over-year increase in revenues in its most recent quarter and clocked nearly a 20 percent...
-
Imprimis Signs Agreement With One Of Nation's Largest Pharmacy Benefit Managers; CEO Talks Disruption
Tuesday, November 22, 2016 - 4:44pm | 709Pharmaceutical compounder Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) first stepped onto the national stage in December 2015, when the company announced its partnership with Express Scripts Holding Company (NASDAQ: ESRX) to distribute a $1 Daraprim alternative following Martin Shkreli and Turing...
-
Benzinga Talks With Imprimis Pharmaceuticals' CEO About Earnings, MKO Melt, Drug Pricing And More
Monday, August 22, 2016 - 9:07am | 708Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) owns, markets and dispenses a portfolio of compounded therapeutic in various areas, including ophthalmology, urology, otolaryngology and infectious diseases. Benzinga had the privilege of chatting with the company's CEO, Mark Baum, about its most recent...
-
Imprimis Pharma CEO Talks Valeant Price 'Jacking,' Says His Co. Will Double Revenue This Quarter
Wednesday, March 9, 2016 - 5:25pm | 1237Imprimis Pharmaceuticals (NASDAQ: IMMY) is a growing player in the ophthalmology eye drop market. Benzinga recently spoke with Imprimis CEO Mark Baum about what investors should expect going forward. Benzinga: You had earnings last Thursday, and you mentioned that you see revenue growth...